Original sentence: However, over 2020-22 with further clinical research, remdesivir had been approved for treatment of hospitalized people with COVID-19 in the United States, European Union, and multiple other countries.In 2021, remdesivir (tradename Veklury) generated more than $4.5 billion in annual revenues, and was Gilead's highest selling product.In January 2022, the Canadian component of the WHO international Solidarity Trial reported that in-hospital people with COVID-19 treated with remdesivir had lower death rates (by about 4%) and reduced need for oxygen and mechanical ventilation compared to people receiving standard-of-care treatments.Remdesivir became a candidate for treating COVID-19; at the time the status was granted, fewer than 200,000 Americans had COVID-19, but numbers were climbing rapidly as the COVID-19 pandemic reached the US, and crossing the threshold soon was considered inevitable
Edited sentence: After facing strong reactions, Gilead gave up the "orphan drug" status for remdesivir on March 25.In June 2020, Gilead announced that the price of remdesivir is set at  per vial for governments of developed countries including the United States and  for private insurance companies in the US.On January 21, 2020, the Wuhan Institute of Virology applied for a Chinese "use patent" on remdesivir, for the novel use of treating COVID-19.Remdesivir is a candidate for treating COVID-19; at the time the status was granted, fewer than 200,000 Americans had COVID-19, but numbers were climbing rapidly as the COVID-19 pandemic reached the US, and crossing the threshold soon was considered inevitable.Remdesivir was developed by Gilead with over $79 million in U.The expected course of treatment is six vials over five days for a total cost of.government funding